NCT05390515

Psoriatic Immune Response to Tildrakizumab

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

Detailed description

This is a one-arm, open-label study to examine the effect of Tildrakizumab on cutaneous and blood immune cells of psoriatic patients. Ten subjects with moderate to severe psoriasis will be enrolled. Biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for tildrakizumab-corrected signatures.

Conditions

• Psoriasis Vulgaris

Interventions

Type	Name	Description
DRUG	Tildrakizumab Prefilled Syringe	IL-23 inhibitor

Timeline

• Start date: 2022-09-01
• Primary completion: 2025-09-01
• Completion: 2025-09-01
• First posted: 2022-05-25
• Last updated: 2023-08-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study